Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06537427
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-01
Brief Title:
The Crosstalk Between the Epigenome and Mitochondria in SCI
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Crosstalk Between the Epigenome and Mitochondria as a Novel Therapeutic Target to Counteract Remote Degeneration Induced by Spinal Cord Injury
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CEM-SCI
Brief Summary:
SCI is a devastating neurological disorder for which there are not yet restorative therapies Thus there is a need to explore new therapeutic strategies to treat SCI patients To this end an appropriate selection and enrolment of suitable participants is crucial for the success of the therapeutic protocol The selection of participants in SCI trials is often based on injury categories eg sensorimotor complete vs incomplete and neglects biological aspects eg biomarkers released into the CSF andor blood that may be amenable to specific therapeutic interventions On a biomolecular standpoint it is renown that CNS lacks the ability to sustain a complete regenerative response after damage which is partially due to the inability of damaged neurons to sustain an epigenetic pro-regenerative response
The background of the present protocol study stands in pre-existing data which showed a crosstalk between the epigenome gene and mitochondria activated upon SCI The clinical branch of this study protocol aims to investigate if and how targeted proteomic changes following the acute and chronic phase of SCI may play a role in determining the severity of neurologic impairments as determined with ASIA gradingscale system at the time of patients presentation and in the conversion of ASIA grade during follow-up A previous pilot study conducted by Wichmann et al has shed light on proteomics after SCI enabling a profiling of inflammatory responses after spinal cord injury timing of proteomics changes involved in inflammatory responses and differences between proteins title in CSF and peripheral blood On the other hand authors failed to prove a correlation between inflammatory proteins expression and timing of expression and neurologic status However previous studies proved that proteome expression variations SCI-induced can be detected into patients CSF and serum and that biomarkers released into the CSF andor blood may provide a plethora of information as to the patients biological response to SCI These samples may contain a unique fingerprint that can be used by scientists and clinicians to elucidate the mechanisms underlying irreversible central nervous system CNS degeneration following SCI This could allow treatments to target specific molecules which promote CNS degeneration Within this context the identification of prognostic biomarkers of SCI will help to assign SCI patients to the correct therapeutic treatment that in association with canonical therapies may synergistically act to improve functional recovery
The aim of the present study is to investigate the presence of prognostic markers in SCI patient-derived serum and CSF with respect to a control group of healthy patients
The background of the present protocol study stands in pre-existing data which showed a crosstalk between the epigenome gene and mitochondria activated upon SCI The clinical branch of this study protocol aims to investigate if and how targeted proteomic changes following the acute and chronic phase of SCI may play a role in determining the severity of neurologic impairments as determined with ASIA gradingscale system at the time of patients presentation and in the conversion of ASIA grade during follow-up A previous pilot study conducted by Wichmann et al has shed light on proteomics after SCI enabling a profiling of inflammatory responses after spinal cord injury timing of proteomics changes involved in inflammatory responses and differences between proteins title in CSF and peripheral blood On the other hand authors failed to prove a correlation between inflammatory proteins expression and timing of expression and neurologic status However previous studies proved that proteome expression variations SCI-induced can be detected into patients CSF and serum and that biomarkers released into the CSF andor blood may provide a plethora of information as to the patients biological response to SCI These samples may contain a unique fingerprint that can be used by scientists and clinicians to elucidate the mechanisms underlying irreversible central nervous system CNS degeneration following SCI This could allow treatments to target specific molecules which promote CNS degeneration Within this context the identification of prognostic biomarkers of SCI will help to assign SCI patients to the correct therapeutic treatment that in association with canonical therapies may synergistically act to improve functional recovery
The aim of the present study is to investigate the presence of prognostic markers in SCI patient-derived serum and CSF with respect to a control group of healthy patients
Detailed Description:
SCI is a devastating neurological disorder for which there are not yet restorative therapies Thus there is a need to explore new therapeutic strategies to treat SCI patients To this end an appropriate selection and enrolment of suitable participants is crucial for the success of the therapeutic protocol 12 The selection of participants in SCI trials is often based on injury categories eg sensorimotor complete vs incomplete and neglects biological aspects eg biomarkers released into the CSF andor blood that may be amenable to specific therapeutic interventions On a biomolecular standpoint it is renown that CNS lacks the ability to sustain a complete regenerative response after damage which is partially due to the inability of damaged neurons to sustain an epigenetic pro-regenerative response 3
The background of the present protocol study stands in pre-existing data which showed a crosstalk between the epigenome gene and mitochondria activated upon SCI In particular previous experimental studies conducted on mice red nuclei RN demonstrated proteome changes at 7 days and 28 days post-SCI Further pathway analysis pointed out to the epigenetic enzyme KDM5A as the upstream regulator of this phenotype KDM5A is a H3K4me3 demethylase protein that plays a fundamental role in mitochondria biogenesis and function whose activity is regulated by mitochondrial metabolites 45 Thereby preliminary data suggest that downregulation of KDM5A activity and increased mitochondrial metabolism are involved in early neuronal response to remote damage However its role in brain pathologies such as in SCI remains still unexplored Since it is well-established that structural and functional damages of mitochondria is an early event that contributed to neuronal cell death hindering the possibility of axonal regeneration 6 the molecular background of the experimental branch of the present protocol study stands in the investigation of epigenetic regulation by KDM5A and mitochondrial function The clinical branch of this study protocol aims to investigate if and how targeted proteomic changes following the acute and chronic phase of SCI may play a role in determining the severity of neurologic impairments as determined with ASIA grading scale system at the time of patients presentation and in the conversion of ASIA grade during follow-up A previous pilot study conducted by Wichmann et al has shed light on proteomics after SCI enabling a profiling of inflammatory responses after spinal cord injury timing of proteomics changes involved in inflammatory responses and differences between proteins title in CSF and peripheral blood On the other hand authors failed to prove a correlation between inflammatory proteins expression and timing of expression and neurologic status 7 However their paper proved that proteome expression variations SCI-induced can be detected into patients CSF and serum and that biomarkers released into the CSF andor blood may provide a plethora of information as to the patients biological response to SCI These samples may contain a unique fingerprint that can be used by scientists and clinicians to elucidate the mechanisms underlying irreversible central nervous system CNS degeneration following SCI This could allow treatments to target specific molecules which promote CNS degeneration Within this context the identification of prognostic biomarkers of SCI will help to assign SCI patients to the correct therapeutic treatment that in association with canonical therapies may synergistically act to improve functional recovery
The aim of the present study is to investigate the presence of prognostic markers in SCI patient-derived serum and CSF with respect to a control group of healthy patients
The background of the present protocol study stands in pre-existing data which showed a crosstalk between the epigenome gene and mitochondria activated upon SCI In particular previous experimental studies conducted on mice red nuclei RN demonstrated proteome changes at 7 days and 28 days post-SCI Further pathway analysis pointed out to the epigenetic enzyme KDM5A as the upstream regulator of this phenotype KDM5A is a H3K4me3 demethylase protein that plays a fundamental role in mitochondria biogenesis and function whose activity is regulated by mitochondrial metabolites 45 Thereby preliminary data suggest that downregulation of KDM5A activity and increased mitochondrial metabolism are involved in early neuronal response to remote damage However its role in brain pathologies such as in SCI remains still unexplored Since it is well-established that structural and functional damages of mitochondria is an early event that contributed to neuronal cell death hindering the possibility of axonal regeneration 6 the molecular background of the experimental branch of the present protocol study stands in the investigation of epigenetic regulation by KDM5A and mitochondrial function The clinical branch of this study protocol aims to investigate if and how targeted proteomic changes following the acute and chronic phase of SCI may play a role in determining the severity of neurologic impairments as determined with ASIA grading scale system at the time of patients presentation and in the conversion of ASIA grade during follow-up A previous pilot study conducted by Wichmann et al has shed light on proteomics after SCI enabling a profiling of inflammatory responses after spinal cord injury timing of proteomics changes involved in inflammatory responses and differences between proteins title in CSF and peripheral blood On the other hand authors failed to prove a correlation between inflammatory proteins expression and timing of expression and neurologic status 7 However their paper proved that proteome expression variations SCI-induced can be detected into patients CSF and serum and that biomarkers released into the CSF andor blood may provide a plethora of information as to the patients biological response to SCI These samples may contain a unique fingerprint that can be used by scientists and clinicians to elucidate the mechanisms underlying irreversible central nervous system CNS degeneration following SCI This could allow treatments to target specific molecules which promote CNS degeneration Within this context the identification of prognostic biomarkers of SCI will help to assign SCI patients to the correct therapeutic treatment that in association with canonical therapies may synergistically act to improve functional recovery
The aim of the present study is to investigate the presence of prognostic markers in SCI patient-derived serum and CSF with respect to a control group of healthy patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None